• All
  • Important
  • Financial Update
  • Fund Raise
  • Board Meeting
  • Dividend/Bonus
  • JV/Acquisition
  • Investor Meet
  • Insider Trade
  • Pledging
  • Others
    ALPHA TRIBE

    Zydus Lifesciences Limited — Updates, 01-10-2025: Press Release

    01-10-2025 | 05:49 pm

    Zydus's subsidiary, Sentynl, faced a development setback for its Menkes disease drug, CUTX-101, due to manufacturing facility inspection findings. Drug efficacy and safety are not concerns. Sentynl will address feedback and pursue resubmission.

    No comments yet. Be the first to comment!

    All announcements from Zydus Lifesciences Limited